Lupin healthcare (UK) Acquires Renascience Pharma to Expand Branded portfolio in the uk
Lupin Healthcare (UK) Limited, the wholly owned subsidiary of global pharmaceutical leader Lupin Limited, has announced the acquisition of Renascience Pharma Limited, a UK-based pharmaceutical company specializing in niche, specialty treatments. With this acquisition, Lupin strengthens its presence in the UK’s branded pharmaceuticals market and expands its commitment to addressing unmet medical needs.
Renascience, known for its targeted portfolio of four specialty products, will now operate as a subsidiary of Lupin Healthcare (UK) Limited. Its current product offerings include branded injectable cephalosporins used in the treatment of infectious diseases, a topical medication for ear pain, and a quinazoline-like diuretic indicated for cardiovascular and renal conditions.
The acquisition marks a strategic move by Lupin to deepen its branded medicine capabilities in the UK, where the company has been steadily growing its footprint. By integrating Renascience’s focused product line, Lupin aims to provide more comprehensive solutions to healthcare providers and patients while contributing value to the NHS (National Health Service).
“In recent years, Lupin has established a highly successful branded business in the UK, delivering significant value to patients and the NHS,” said Fabrice Egros, President of Corporate Development at Lupin. “This strategic move allows Lupin to further enhance our branded medicine portfolio, catering to unmet medical needs and furthering our mission to provide accessible and sustainable healthcare solutions.”
The deal underscores Lupin’s ongoing global expansion strategy, particularly in developed markets, and reflects the company’s focus on high-value, specialty medications.
As the UK healthcare landscape continues to evolve, Lupin’s acquisition of Renascience positions the company to play a greater role in delivering innovative, affordable, and essential medicines to patients across the country.
Co-founder & Director of Renascience, Eric che commented, “Renascience was founded with the goal to improve patient access to speciality, critical medicines and we are extremely proud of what we have been able to revive to date for the benefit of patients. As we looked forward to the future, it was deeply important that Renascience has the best opportunity to build on what has been accomplished and expand its reach to improve outcomes for as many patients as possible, and we are pleased to have found that opportunity with Lupin. Lupin has the cultural fit, capabilities and experience for the next stage of growth, and we are excited to see the products go from strength to strength.”
